Dae-Won Kim

Yonsei University

Dae-Won Kim is committed to the discovery and validation of novel therapeutic genes for the treatment of degenerative diseases through AAV (Adeno-Associated Virus) gene therapy. Driven by the pressing unmet medical needs in this field, his current research aims to develop innovative disease intervention strategies that address the underlying mechanisms of tissue degeneration, rather than merely providing symptomatic relief. By integrating cutting-edge molecular techniques with rigorous preclinical validation platforms, his work seeks to establish transformative, durable therapies that deliver meaningful clinical benefits to patients affected by these debilitating conditions. The primary areas of focus include: Joint degeneration, such as osteoarthritis (OA), age-related macular degeneration (AMD) and sensorineural hearing loss. The overarching objective of this research is to develop disease-modifying gene therapies capable of restoring tissue integrity and function, which, in turn, can alter the natural course of these chronic and severe disorders.